Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



Blogosphere on NEJM and Vioxx

Derek Lowe on the co-authors' response to the NEJM editorial on Vioxx:

Looking at everything together, I'm still coming down on the side of Merck and their academic collaborators in this part of the fight. The post-launch cardiovascular data on Vioxx and its advertising and promotion are worth debating separately, but as for the VIGOR study, I think the NEJM is overreaching. Still, from Merck's viewpoint, I think the damage has already been done. . .

Update: Y'know, it occurs to me that there are a few people who aren't as upset about all this editorial wrangling: the editors of JAMA and the other top-ranked medical journals. They'll be getting some manuscripts that otherwise would have gone to NEJM.

Commenter tgibbs: "I lean toward the explanation that the editors of NEJM are simply statistically illiterate." Also out there: Jim Hu, Janet Stemwedel, and Kevin MD.

See Point of Law Feb. 22 and links therein.



Rafael Mangual
Project Manager,
Legal Policy

Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.